| pubmed-article:12237621 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12237621 | lifeskim:mentions | umls-concept:C0029456 | lld:lifeskim |
| pubmed-article:12237621 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:12237621 | lifeskim:mentions | umls-concept:C0732611 | lld:lifeskim |
| pubmed-article:12237621 | lifeskim:mentions | umls-concept:C1705413 | lld:lifeskim |
| pubmed-article:12237621 | lifeskim:mentions | umls-concept:C0332281 | lld:lifeskim |
| pubmed-article:12237621 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:12237621 | lifeskim:mentions | umls-concept:C1550015 | lld:lifeskim |
| pubmed-article:12237621 | lifeskim:mentions | umls-concept:C0666003 | lld:lifeskim |
| pubmed-article:12237621 | lifeskim:mentions | umls-concept:C1609614 | lld:lifeskim |
| pubmed-article:12237621 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:12237621 | pubmed:dateCreated | 2002-9-18 | lld:pubmed |
| pubmed-article:12237621 | pubmed:abstractText | Selective estrogen receptor modulators are novel compounds that bind to the estrogen receptor and have mixed agonistic and antagonistic activities. Recently, an increase in urinary incontinence has been reported with hormone replacement therapy use. A decrease in surgical procedures for pelvic floor relaxation has been recently reported with raloxifene, a selective estrogen receptor modulator that is not uterotropic. Levormeloxifene is a selective estrogen receptor modulator that was developed for the purpose of the treatment and prevention of postmenopausal osteoporosis. | lld:pubmed |
| pubmed-article:12237621 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12237621 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12237621 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:12237621 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12237621 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12237621 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12237621 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12237621 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:12237621 | pubmed:issn | 0002-9378 | lld:pubmed |
| pubmed-article:12237621 | pubmed:author | pubmed-author:GoldsteinStev... | lld:pubmed |
| pubmed-article:12237621 | pubmed:author | pubmed-author:NanavatiNayan... | lld:pubmed |
| pubmed-article:12237621 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12237621 | pubmed:volume | 187 | lld:pubmed |
| pubmed-article:12237621 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12237621 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12237621 | pubmed:pagination | 521-7 | lld:pubmed |
| pubmed-article:12237621 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:12237621 | pubmed:meshHeading | pubmed-meshheading:12237621... | lld:pubmed |
| pubmed-article:12237621 | pubmed:meshHeading | pubmed-meshheading:12237621... | lld:pubmed |
| pubmed-article:12237621 | pubmed:meshHeading | pubmed-meshheading:12237621... | lld:pubmed |
| pubmed-article:12237621 | pubmed:meshHeading | pubmed-meshheading:12237621... | lld:pubmed |
| pubmed-article:12237621 | pubmed:meshHeading | pubmed-meshheading:12237621... | lld:pubmed |
| pubmed-article:12237621 | pubmed:meshHeading | pubmed-meshheading:12237621... | lld:pubmed |
| pubmed-article:12237621 | pubmed:meshHeading | pubmed-meshheading:12237621... | lld:pubmed |
| pubmed-article:12237621 | pubmed:meshHeading | pubmed-meshheading:12237621... | lld:pubmed |
| pubmed-article:12237621 | pubmed:meshHeading | pubmed-meshheading:12237621... | lld:pubmed |
| pubmed-article:12237621 | pubmed:meshHeading | pubmed-meshheading:12237621... | lld:pubmed |
| pubmed-article:12237621 | pubmed:meshHeading | pubmed-meshheading:12237621... | lld:pubmed |
| pubmed-article:12237621 | pubmed:meshHeading | pubmed-meshheading:12237621... | lld:pubmed |
| pubmed-article:12237621 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:12237621 | pubmed:articleTitle | Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study. | lld:pubmed |
| pubmed-article:12237621 | pubmed:affiliation | Department of Obstetrics and Gynecology, New York University School of Medicine, NY, USA. steven.goldstein@med.nyu.edu | lld:pubmed |
| pubmed-article:12237621 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12237621 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:12237621 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:12237621 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:12237621 | pubmed:publicationType | Clinical Trial, Phase III | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12237621 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12237621 | lld:pubmed |
